Home
Recent press, briefings and insights helping you stay informed on AliveDx newest launch.
AliveDx Suisse S.A. and Bio-State Inc. have signed a distribution agreement, which will enable Bio-State Inc. to distribute the MosaiQ® solution in India. The distribution agreement takes effect immediately. This strategic partnership with an important partner in India reaffirms AliveDx’s
Meet the Alba team at the AABB Annual Meeting to learn how our high-quality blood bank reagents can drive value in your lab! Sign up for a booth meeting with your Account Executive today.
Maximizing your valuable time and resources is essential for efficient laboratory operations. Experience firsthand the transformative capabilities of MosaiQ and LumiQ (IFA). Both solutions are designed to deliver actionable diagnostic insights more quickly and cost-effectively, helping you achieve more with
We are proud to announce that our manufacturing facility in Edinburgh, Scotland has been awarded the ISO 22301:2019 Security and resilience certificate. “Gaining the ISO 22301 standard for the UK site underlines AliveDx’s commitment to the needs of our customers.
We are proud to announce that our manufacturing facility in Eysins, Switzerland has been granted ISO 13485:2016 and Medical Device Single Audit Program (MDSAP) certifications for the design, development, production, and distribution of in-vitro diagnostic test kits and reagents for
At AliveDx, our mission is to empower diagnostic insights, transform patient care, and innovate for life. We are excited and proud to announce AliveDx has received IVDR-CE mark certification for its multiplexed MosaiQ AiPlex™ CD microarray immunoassay, designed to improve
Alba Bioscience Inc., part of the AliveDx group, is pleased to announce a distribution agreement with RAF Solutions LA, Inc. to bring its high-quality blood bank reagents to the Latin American market. This strategic partnership reinforces Alba’s commitment to expanding
AliveDx Suisse S.A. and Tabrane Pharmaceuticals (PVT) Limited have signed a distribution agreement, which will enable Tabrane Pharmaceuticals to distribute the MosaiQ® solution in Sri Lanka. The distribution agreement takes effect immediately. AliveDx is dedicated to expanding its reach and
We are proud to announce that our abstract B-073, titled: “Analytical Performance of a Novel, Fully Automated Multiplexed Microarray Immunoassay Prototype for the Simultaneous Detection of Fifteen Autoantibodies Associated with Connective Tissue Diseases” has been awarded the ADLM 2024 Industry
AliveDx Suisse S.A. and Kyungil Hi-tec INC have signed an exclusive distribution agreement, which will enable Kyungil Hi-tec to distribute the MosaiQ® solution in South Korea. The distribution agreement takes effect immediately. This strategic partnership with an important partner in